Both Zeposia and Mayzent are hoping to eat into the market share held by Gilenya, which was a $3.2 billion product last year but saw its first generics approved by the FDA last December.

Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb ...

Today was a day of immense historical significance for me. I had the privilege of attending Independent Living Education Day ...